| Invasive Malignant Neoplasm altered in cohorts of …ALTERED_INderived200 of 490show all (up to 200) |
|---|
| ← altered in cohorts of | MYC 455 / 603 cases (75 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FAM135B 449 / 603 cases (74 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | POU5F1B 449 / 603 cases (74 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ACTRT3 447 / 603 cases (74 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ADCY8 446 / 603 cases (74 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | AGO2 446 / 603 cases (74 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRC34 446 / 603 cases (74 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MYNN 446 / 603 cases (74 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PTK2 446 / 603 cases (74 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GPR20 445 / 603 cases (74 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GSDMC 445 / 603 cases (74 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LRATD2 445 / 603 cases (74 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRC31 445 / 603 cases (74 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRIQ4 445 / 603 cases (74 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PTP4A3 445 / 603 cases (74 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ASAP1 444 / 603 cases (74 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CHRAC1 444 / 603 cases (74 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SAMD7 444 / 603 cases (74 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SEC62 444 / 603 cases (74 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC45A4 444 / 603 cases (74 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TRIB1 444 / 603 cases (74 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | COL22A1 443 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CYRIB 443 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EPPK1 443 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GPR160 443 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KCNK9 443 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KHDRBS3 443 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MECOM 443 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SCRIB 443 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZFAT 443 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | OBSCN 806 / 1,098 cases (73 %) · ssm · TCGA-BRCA · largest of 5 cohorts | — | — | Breast Invasive Carcinoma, NOS | 5 | Observed | gdc | graph → |
| ← altered in cohorts of | CLDN11 442 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DENND3 442 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FAM83H 442 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IQANK1 442 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MAPK15 442 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NRBP2 442 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PARP10 442 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PHC3 442 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRKCI 442 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PUF60 442 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SKIL 442 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC7A14 442 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ST3GAL1 442 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TMEM71 442 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TRAPPC9 442 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZNF623 442 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PIK3C2B 804 / 1,098 cases (73 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CCDC166 441 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CCN4 441 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | COL14A1 441 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EEF1D 441 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EFR3A 441 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GRINA 441 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HGH1 441 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MROH1 441 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | OPLAH 441 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PHF20L1 441 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLEC 441 / 603 cases (73 %) · ssm · TCGA-OV · largest of 5 cohorts | — | — | Ovarian Serous Cystadenocarcinoma | 5 | Observed | gdc | graph → |
| ← altered in cohorts of | PYCR3 441 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLA 441 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SPATC1 441 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TIGD5 441 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TSNARE1 441 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | WASHC5 441 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZC3H3 441 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZNF707 441 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRN2 803 / 1,098 cases (73 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MDM4 803 / 1,098 cases (73 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NFASC 803 / 1,098 cases (73 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NID1 803 / 1,098 cases (73 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLEKHA6 802 / 1,098 cases (73 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BOP1 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CYC1 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EIF5A2 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EXOSC4 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GFUS 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GPAA1 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GSDMD 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HHLA1 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KCNQ3 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRC6 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MAFA 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MROH6 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NAPRT 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NDRG1 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NSMCE2 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | OC90 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLD1 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RPL22L1 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SCX 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SHARPIN 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SQLE 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TNIK 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TONSL 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | WDR97 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZNF572 440 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PPP1R15B 801 / 1,098 cases (73 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ASPM 800 / 1,098 cases (73 %) · ssm · TCGA-BRCA · largest of 2 cohorts | — | — | Breast Invasive Carcinoma, NOS | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | CDK18 800 / 1,098 cases (73 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ADGRB1 439 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CYP11B2 439 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LY6E 439 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC2A2 439 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC39A4 439 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | VPS28 439 / 603 cases (73 %) · ssm · TCGA-OV | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CHI3L1 799 / 1,098 cases (73 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CNTN2 799 / 1,098 cases (73 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DSTYK 799 / 1,098 cases (73 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EXOC8 799 / 1,098 cases (73 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LYST 799 / 1,098 cases (73 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC35F3 799 / 1,098 cases (73 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TMCC2 799 / 1,098 cases (73 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TMEM81 799 / 1,098 cases (73 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ATP2B4 798 / 1,098 cases (73 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BLACAT1 798 / 1,098 cases (73 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GNPAT 798 / 1,098 cases (73 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GOLT1A 798 / 1,098 cases (73 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KISS1 798 / 1,098 cases (73 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LEMD1 798 / 1,098 cases (73 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NUAK2 798 / 1,098 cases (73 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RAB29 798 / 1,098 cases (73 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RBBP5 798 / 1,098 cases (73 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZC3H11A 798 / 1,098 cases (73 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C1orf131 797 / 1,098 cases (73 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DISC1 797 / 1,098 cases (73 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ETNK2 797 / 1,098 cases (73 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCMR 797 / 1,098 cases (73 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IRF2BP2 797 / 1,098 cases (73 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KLHDC8A 797 / 1,098 cases (73 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MFSD4A 797 / 1,098 cases (73 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NUCKS1 797 / 1,098 cases (73 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PFKFB2 797 / 1,098 cases (73 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PIGR 797 / 1,098 cases (73 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | REN 797 / 1,098 cases (73 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC26A9 797 / 1,098 cases (73 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC41A1 797 / 1,098 cases (73 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SOX13 797 / 1,098 cases (73 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SPRTN 797 / 1,098 cases (73 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TOMM20 797 / 1,098 cases (73 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TRIM67 797 / 1,098 cases (73 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ADIPOR1 796 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ARID4B 796 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | COA6 796 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CYB5R1 796 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EGLN1 796 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ELK4 796 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ESRRG 796 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FAM89A 796 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FMOD 796 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GALNT2 796 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HEATR1 796 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KCNT2 796 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KLHL12 796 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PCNX2 796 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PM20D1 796 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRELP 796 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RBM34 796 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SIPA1L2 796 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC45A3 796 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SYT2 796 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TBCE 796 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TMEM183A 796 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ARV1 795 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | B3GALNT2 795 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BTG2 795 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C1orf116 795 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C4BPB 795 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CDC42BPA 795 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CFH 795 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CHIT1 795 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DENND1B 795 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DNAH14 795 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ENAH 795 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCAMR 795 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GNG4 795 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IKBKE 795 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IL19 795 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IL20 795 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IL24 795 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LAX1 795 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LBR 795 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MAP10 795 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MYBPH 795 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | OPTC 795 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PPFIA4 795 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PSEN2 795 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SNRPE 795 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TARBP1 795 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TTC13 795 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | YOD1 795 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZBED6 795 / 1,098 cases (72 %) · ssm · TCGA-BRCA | — | — | Breast Invasive Carcinoma, NOS | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CCAR2 298 / 500 cases (60 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BIN3 297 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C8orf58 297 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | XPO7 297 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BMP1 296 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PEBP4 296 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PIWIL2 296 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PPP3CC 296 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |